Odesivimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetZaire ebolavirus glycoprotein
Clinical data
Pronunciationoh" de siv' i mab
License data
Drug classMonoclonal antibody
ATC code
  • None
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
FormulaC6506H10024N1720O2030S42
Molar mass146164.29 g·mol−1

Odesivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).[1][2]

References

  1. ^ "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.

External links


Monoclonal antibodies for infectious disease and toxins
More
Categories